Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
Dexcom Inc (DXCM) is a leader in continuous glucose monitoring systems, transforming diabetes care through real-time health data solutions. This page consolidates official announcements, financial updates, and strategic developments for stakeholders tracking the company’s progress in medical technology.
Access timely updates on product innovations, regulatory milestones, and partnership agreements that shape Dexcom’s position in the diabetes management sector. Investors will find earnings reports and market analyses, while healthcare professionals can monitor clinical trial outcomes and device enhancements.
Key content includes FDA clearances, international expansion updates, and technology integration developments with insulin delivery systems. All materials are sourced from verified channels to ensure reliability for research and decision-making.
Bookmark this page for streamlined access to Dexcom’s latest advancements in CGM technology and related financial performance. Check regularly for critical updates that impact both patient care and investment considerations.
Dexcom announced that Nova Scotia now provides coverage for Dexcom G6 and G7 continuous glucose monitoring (CGM) systems for residents with type 1 or type 2 diabetes who use intensive insulin and meet eligibility criteria.
This is part of the province's Pharmacare programs and a new income-based Sensor-Based Glucose Monitoring Program, aimed at reducing out-of-pocket costs for diabetes management tools.
Nova Scotia joins other provinces like New Brunswick, Newfoundland and Labrador, British Columbia, Manitoba, and Prince Edward Island in offering such coverage.
Dexcom's CGM systems, including the newly introduced G7, are clinically proven to reduce A1C, improve time in range, and reduce hypoglycemic events.
Dexcom (NASDAQ: DXCM) announced that its Executive Vice President and Chief Financial Officer, Jereme Sylvain, will present an update at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th.
The presentation will start at 4:20 PM EST and will be available via live webcast. The webcast can be accessed through the Dexcom Investor Relations website and will be archived for future reference.
Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.
This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.
Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.
This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.
Dexcom has launched the Dexcom ONE+ sensor in the UK, incorporating 25 years of research to assist individuals with Type 2 diabetes in monitoring their glucose levels in real-time. The first-ever 'Dexcom State of Type 2 Report' reveals that a significant number of people with Type 2 diabetes experience anxiety and depression, and many struggle to manage their condition effectively. The report highlights that 54% of respondents wish they had more confidence in managing their diabetes, and 63% face challenges in improving their diet or mental health. Additionally, 48% of participants believe glucose monitoring could improve their condition management.
Dexcom ONE+ aims to provide a tailored solution for people with Type 2 diabetes, enhancing user motivation and diabetes management by providing real-time feedback. The report is intended to serve as a resource for healthcare professionals and empower those with Type 2 diabetes to feel less isolated.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
